Preliminary results indicate HHT patients are significantly impacted by bleeding events, with consistency in severity reporting at months one and three of the study Final study analysis will inform ...

Study conducted in partnership with Cure HHT will inform future clinical trials and treatment options for people living with HHT Company recently progressed DIAG723 into IND-enabling studies for HHT ...

A clinical trial supported by the National Institutes of Health (NIH) was stopped early after researchers found sufficient evidence that a drug called pomalidomide, which is used to treat bone marrow ...

‍HHT is a rare disease that affects more than 150,000 people in the U.S. and EU, and for which there are currently no approved therapies. In HHT, loss-of-function point mutations in members of the TGF ...

Hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, is a rare, but serious, genetic disorder that causes abnormal blood vessels to form throughout the body. These ...

PITTSBURGH (KFSN) -- HHT is a genetic disorder of the blood vessels. In severe cases, it can lead to sudden bleeding or stroke. Researchers say HHT affects more than one in 5,000 people, but 90 ...

SAN DIEGO -- In a randomized trial, pomalidomide (Pomalyst) significantly reduced severe nosebleeds in patients with hereditary hemorrhagic telangiectasia (HHT), a condition with no approved therapy.

LAFFAYETTE, NJ – A local family has taken their personal story and turned it into a fundraising event. Sparta High School Athletic Director Steve Stoner’s uncle has a blood disorder known as HHT. They ...

Preliminary results indicate HHT patients are significantly impacted by bleeding events, with consistency in severity reporting at months one and three of the study Final study analysis will inform ...